What does CUSIP 297584112 represent in this 13F holders report?

CUSIP 297584112 is the security identifier for ESLAW - Estrella Immunopharma, Inc. - *W EXP 09/29/202 used to aggregate holder disclosures.

How many institutions held ESLAW - Estrella Immunopharma, Inc. - *W EXP 09/29/202 in Q3 2023?

1 institutional investor reported ESLAW - Estrella Immunopharma, Inc. - *W EXP 09/29/202 for Q3 2023. Use the holders table for investor-level position and value details.

202 (ESLAW)

CUSIP: 297584112

Q3 2023 13F Holders as of 30 Sep 2023

Security type / class: Equity / *W EXP 09/29/202
Total 13F shares: 11,805
Total 13F value: $1,745
Share change: +11,805
SEC-reported price per share: $0.15
Number of holders: 1
Value change: +$1,745
Number of buys: 1

Security key

297584112

Report period

Q3 2023

Institutions

Top holders

ESLAW full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2026 Estrella Immunopharma, Inc. SEC filings Estrella Immunopharma, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 297584112

Newer quarter: Q3 2026

Recent filing periods:

Q3 2026

Ownership snapshot

Top reported holders of ESLAW - Estrella Immunopharma, Inc. - *W EXP 09/29/202 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Eureka Therapeutics, Inc.

Disclosed value leader

—

Comparable rows

0/6

Latest evidence

29 Sep 2023

3/4/5 Some rows are evidence-backed but not safely comparable across classes. 6 rows are not safely comparable across share classes.

Quick read

SEC ownership evidence is available, but the rows are not safely comparable across share classes.

0 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Eureka Therapeutics, Inc.'s linked filing trail.

Detailed SEC evidence table Showing 1-6 of 6 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Eureka Therapeutics, Inc.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	— 25,277,831 shares	—	29 Sep 2023
TradeUP Acquisition Sponsor LLC	3/4/5 Former 10% owner 3/4/5	— denominator unverified	— 1,145,760 shares	—	29 Sep 2023
Jianwei Li	3/4/5 Former Co-CEO and Director 3/4/5	— denominator unverified	— 1,253,730 shares	—	29 Sep 2023
James Long	3/4/5 Former Director 3/4/5	— denominator unverified	— 10,000 shares	—	29 Sep 2023
Tao Jiang	3/4/5 Former Director 3/4/5	— denominator unverified	— 10,000 shares	—	29 Sep 2023
Weston Twigg	3/4/5 Former Director 3/4/5	— denominator unverified	— 10,000 shares	—	29 Sep 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

11,805

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders

Q3 2023 holders

Holder diff

Investor	Q2 2023 Shares	Q3 2023 Shares	Share Diff	Share Chg %	Q2 2023 value	Q3 2023 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend